GlycoMimetics (NASDAQ: GLYC) recently said that it will present preclinical research suggesting the vast potential of two of its drug candidates, GMI-1271 and GMI-1359, via poster presentations at the American Association for Cancer Research (“AACR”) Annual Meeting 2018 taking place April 16-18 in Chicago, Illinois. The data to be presented shows the potential of GMI-1359 in treating osteosarcoma and other cancers and the potential to expand the use of GMI-1271 in patients with acute myeloid leukemia (“AML”) who are unfit for chemotherapy. “The new preclinical studies indicate a greater range of opportunities to potentially use our drug candidates to treat AML patients unable to withstand intensive chemotherapy, and also potentially to treat other cancers, such as osteosarcoma, that have resisted other therapies,” GlycoMimetics Senior Vice President and Chief Scientific Officer John Magnani, Ph.D., stated in the news release.
To view the full press release, visit http://nnw.fm/BG0uj
About GlycoMimetics
GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial conducted by GlycoMimetics’ strategic collaborator, Pfizer, with preliminary data expected in the second half of 2018. The FDA granted Breakthrough Therapy designation for the company’s wholly owned drug candidate, GMI-1271, an E-selectin antagonist, for treatment of adult AML patients with relapsed/refractory disease; a Phase 3 clinical trial is planned to initiate in the third quarter of 2018. GMI-1271 is also being evaluated in an ongoing Phase 1 clinical trial for the treatment of multiple myeloma. GlycoMimetics has also initiated a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. For more information, visit the company’s website at www.glycomimetics.com.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]